A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

TCR Signal Strength and Duration In Primary Mouse CD8+ T Cell Activation and Differentiation: A Standardized In Vitro Approach

150 views

⸱

DOI:

10.3791/71979

⸱

August 25th, 2026

* These authors contributed equally

In This Article

Summary

This protocol describes a systematic method to activate primary mouse naive CD8+ T cells using a graded TCR stimulation approach, enabling comprehensive analysis of proliferation, activation, and cytokine production of CD8+ T cells across different TCR signal intensities.

Abstract

T cell receptor (TCR) signal intensity and duration are critical determinants of CD8⁺ T cell activation, proliferation, and functional differentiation. However, standardized in vitro models that systematically compare how varying TCR signal inputs shape T cell fate remain limited. This study presents a reproducible method for activating primary mouse T cells in vitro using plate-bound anti-CD3 and soluble anti-CD28, supplemented with interleukin-2 (IL-2), and examines how modulating anti-CD3 concentration (signal strength) and stimulation time (signal duration) influences activation outcomes of T cells. We detail a protocol for isolating naive T cells from C57BL/6 mice, followed by stimulation across a range of anti-CD3 concentrations (0.1–10 µg/mL) and durations (6–48 h). We conducted flow cytometric analysis to assess early TCR-induced signaling via intracellular phosphorylated S6 ribosomal protein (p-S6) as a readout of mechanistic target of rapamycin complex 1 (mTORC1) activity, and then evaluated downstream events including surface activation markers (CD69, CD25, ICOS, PD-1), cellular proliferation via violet proliferation-tracking dye (CTV) dilution, and effector molecule expression (Granzyme B, TNF-α) as indicators of functional differentiation. The method provides a clear, stepwise visual guide for executing reproducible T cell stimulations, enabling researchers to dissect how specific TCR signal parameters direct T cell fate decisions. This approach not only supports mechanistic studies of T cell activation and differentiation but also offers a platform for optimizing T cell conditioning for adoptive immunotherapy and in vitro priming assays. By integrating video demonstration with detailed protocol narration, this protocol will enhance methodological transparency and reproducibility in T cell immunology research.

Introduction

T cells are indispensable for protective immune responses against pathogens and tumors. Naive T cells are actively maintained in a quiescent state to preserve their long-term survival and persistence1. Upon antigen stimulation, T cells exit quiescence, undergo clonal expansion and effector differentiation2. T cell receptor (TCR) signaling serves as the core process for initiating and regulating adaptive immune responses3. Upon specific recognition of peptide-major histocompatibility complex (pMHC) molecules presented on the surface of antigen-presenting cells (APCs), a cascade of signaling events is triggered, thereby driving clonal expansion and functional differentiation of T cells4,5,6.

The intensity of TCR stimulation, determined by key factors including antigen affinity, avidity, and concentration, plays a critical role in governing the magnitude of T cell activation, the acquisition of effector functions, and the differentiation trajectory toward distinct effector or memory T cell subsets7,8,9. Current in vitro models for investigating TCR-dependent T cell activation predominantly employ plate-bound or bead-conjugated anti-CD3 and anti-CD28 antibodies, which provide both TCR ligation and co-stimulatory signals simultaneously10,11. Although such systems are widely used, they typically utilize only a single, often saturating concentration of anti-CD3 antibody, permitting merely an all-or-nothing binary comparison of T cell activation, rather than capturing the dynamic range of TCR signal strengths achievable with a titrated gradient of stimuli12,13.

The protocol described herein provides a standardized and reproducible in vitro system to systematically evaluate how graded TCR signal strengths modulate activation, proliferation, and functional phenotypes of primary murine CD8+ T cells, using titrated anti-CD3 gradients (0.1–10 µg/mL) and a constant anti-CD28 (1 µg/mL). This approach centers on multiparameter flow cytometry that captures both upstream signaling—via intracellular phosphorylated S6 ribosomal protein (p-S6) as a readout of mechanistic target of rapamycin complex 1 (mTORC1) activity—and downstream cellular outcomes, including proliferation tracked by CTV dilution, activation surface markers (CD69, CD25, inducible T-cell costimulatory [ICOS], programmed cell death protein 1 [PD-1]), and effector molecule expression (Granzyme B, tumor necrosis factor-alpha [TNF-α]), over a time course from 6 to 48 h.

Our protocol employs a gradient concentration of plate-bound anti-CD3 antibodies to precisely modulate stimulation intensity, thereby mimicking the differential TCR binding avidity observed under physiological conditions. The method achieves high efficiency in TCR crosslinking and robust activation of primary resting T cells. The standardized coating procedure ensures uniform antibody distribution on the plate surface, leading to consistent stimulation across cells within the same batch and excellent experimental reproducibility. This format provides a cost-effective and operationally simple approach for T cell activation.

However, certain limitations of this approach should be acknowledged. Stimulation mediated by anti-CD3/CD28 antibodies differs markedly from the in vivo physiological context. Although experimental methods that use only agonistic anti-CD3 and anti-CD28 antibodies to assess T cell activation can provide effective readouts of activation, they fail to fully recapitulate the interactions between antigen-presenting cells and T cells, as well as the co-stimulatory microenvironment that occur under physiological conditions14.

Despite these limitations, this protocol offers a systematic and reproducible platform that serves as a valuable and accessible tool for investigating TCR signal strength-dependent T cell responses and can complement more complex antigen-specific models.

Access restricted. Please log in or start a trial to view this content.

Protocol

All animal experiments in this study were approved by the Animal Care and Use Committee of Third Military Medical University.

1. Preparation of reagents and plates

  1. Prepare plate-bound anti-CD3 in sterile PBS at 0.1, 0.5, 1, 5, and 10 µg/mL.
  2. Add 50 µL of the anti-CD3 coating solution per well into flat-bottom 96-well plates.
  3. Seal plates with sealing film and incubate overnight at 4 °C.
  4. Aspirate the coating solution and wash each well twice with 200 µL of sterile PBS before adding cells.

2. Isolation of naive CD8+ T cells from mouse spleen

  1. Select 6–8-week-old male C57BL/6 mice (purchased from Sibeifu (Beijing) Biotechnology Co., Ltd.) and euthanize by CO2 inhalation followed by cervical dislocation. Mice are housed under specific pathogen-free conditions with a 12-h light/dark cycle and free access to food and water. A minimum of 3 mice are used per independent experiment.
  2. Carefully incise the peritoneum with surgical scissors to expose the spleen, grasp and harvest the spleen using forceps, and place it into a collection dish containing pre-chilled RPMI 1640 supplemented with 2% fetal bovine serum(FBS) (R2). Keep the dish on ice until dissociation.
    NOTE: Collect all animal carcasses and cell culture waste in designated biohazard bags and autoclave them at 121 °C for 20 min before disposal.
  3. Remove the spleen from the collection dish and transfer it into a 60 mm dish containing 3 mL of 1 × ammonium-chloride-potassium (ACK) lysis buffer.
  4. Prepare a single-cell suspension by gently mashing the spleen through a 70 µm cell strainer using the plunger of a 3 mL syringe.
  5. Incubate the suspension for 1 min at room temperature(RT), then add 3 mL of pre-chilled R2 medium to neutralize the ammonium-chloride-potassium (ACK) lysis buffer.
  6. Transfer the cell suspension to a 15 mL conical tube and centrifuge at 500 × g for 5 min at 4 °C.
  7. After centrifugation, aspirate the supernatant and resuspend the pellet in 10 mL of flow cytometry staining buffer (PBS with 2% FBS).
  8. Filter the suspension through a 70 µm cell strainer into a new 15 mL conical tube, then centrifuge again at 500 × g for 5 min at 4 °C.
    NOTE: Sodium azide should be omitted from flow cytometry staining buffer to preserve cell viability for functional assays. All samples should be kept at 4 °C and analyzed immediately.
  9. Aspirate the supernatant and resuspend the cell pellet in 200 µL of biotinylated antibody cocktail per mouse spleen (containing anti-CD16/32 (Fc block), anti-TER-119, anti-CD19, anti-CD4, anti-B220, anti-NK1.1, anti-Ly-6G, anti-CD11b, anti-CD11c, anti-CD49b, anti-CD44 and anti-F4/80).
  10. Incubate on ice for 25 min with gentle inversion of the tube every 5 min to ensure thorough mixing.
  11. Wash the cells with a large volume of flow cytometry staining buffer, centrifuge at 500 × g for 5 min and discard the supernatant.
  12. Resuspend the pellet in the same volume of flow cytometry staining buffer as used for biotinylated antibody cocktail, add streptavidin-coated magnetic beads at half that volume, and incubate on ice for 15 min with gentle inversion of the tube every 5 min to ensure thorough mixing.
  13. Briefly centrifuge the tube, place it on a magnetic stand for 2–3 min, and carefully transfer the supernatant (enriched naive CD8+ T cells) to a new 15 mL conical tube.
  14. Wash the collected cells once with flow cytometry staining buffer, centrifuge again at 500 × g for 5 min.
  15. Discard the supernatant and resuspend the pellet in RPMI 1640 supplemented with 10% FBS (R10) for downstream applications.

3. Violet proliferation-tracking dye (CTV) labeling for proliferation tracking

  1. Prepare 2 × fresh CTV working solution (10 µM) immediately before use. Fully mix the 5 mM CTV stock solution (in dimethyl sulfoxide [DMSO]) by vortexing and further dilute it with sterile PBS to obtain a final concentration of 10 µM.
    CAUTION: Handle CTV stock solution (prepared in DMSO) with nitrile gloves in a fume hood, as DMSO facilitates skin absorption of toxic compounds. Avoid inhalation and skin contact.
  2. Resuspend half of the isolated naive CD8+ T cells in pre-chilled PBS at a density of 8 × 107 cells/mL.
  3. Rapidly add an equal volume of 2 × CTV working solution (10 µM) to the cell suspension and mix well by pipetting, yielding a final CTV concentration of 5 µM.
  4. Incubate the cells at RT in the dark for 20 min, with gentle inversion of the tubes every 5 min to ensure thorough mixing.
  5. Add 5 volumes of culture medium (containing at least 10% FBS) to the cells and incubate for 5 min on ice to remove any free dye.
  6. Centrifuge cells at 500 × g for 5 min and resuspend the pellet in freshly pre-warmed complete medium R10 supplemented with anti-CD28 (final concentration: 1 µg/mL) and IL-2 (final concentration: 10 ng/mL).
  7. Add 250 µL of cell suspension (containing 6 × 105cells) to each well of the pre-coated 96-well plates.
  8. Culture cells at 37 °C with 5% CO₂ for up to 48 h.

4. CTV detection by flow cytometry

  1. Collect cells into a 96-well round-bottom plate at 6, 36, and 48 h. Centrifuge at 500 × g for 5 min and wash twice with flow cytometry staining buffer.
  2. For surface staining, incubate cells with 50 µL of an antibody cocktail containing anti-CD8, fixable viability dye, and anti-CD44 for 30 min on ice in the dark.
    NOTE: Collect all supernatants containing fluorophore-conjugated antibodies in designated waste containers supplemented with 0.5% sodium hypochlorite for decontamination and discard them according to institutional biohazardous waste protocols.
  3. Wash cells twice with flow cytometry staining buffer and resuspend in 200 µL of flow cytometry staining buffer for flow cytometer acquisition.
  4. Acquire samples on a flow cytometer equipped with three lasers. Prepare single-color control tubes using stained cells to set compensation parameters.
  5. Apply the following gating strategy: exclude debris by forward-scatter (FSC) versus side-scatter (SSC) gating, eliminate doublets by singlet gating, and select viable (fixable viability dye-negative) CD8+ T cells for analysis.
  6. Collect at least 1 × 104 gated CD8+ T cell events per sample. Analyze the data using the flow cytometry analysis software and calculate the proportion of cells that have undergone one or more divisions using the proliferation analysis module.

5. Surface and intracellular staining for activation and signaling

  1. Resuspend another half of naive CD8+ T cells in R10 supplemented with anti-CD28 at 1 µg/mL and IL-2 at 10 ng/mL at 2.4 × 106 cells/mL.
  2. Add 250 µL of cell suspension (6 × 105cells) to each well of the pre-coated 96-well plates.
  3. Culture cells at 37 °C with 5% CO₂ for up to 48 h.
  4. At indicated time points (6, 10, 12, 24, and 36 h), collect cells into a 96-well round-bottom plate.
    NOTE: 6 h captures early TCR signaling (phospho-S6) and CD69; the latter is additionally assessed at 12, 24, and 36 h to capture its full kinetics. CD25, PD-1, and ICOS are monitored at 10, 12, 24, and 36 h; the 48 h time point is reserved for proliferation (Section 4) and cytokine detection (Section 6).
  5. Centrifuge at 500 × g for 1 min and resuspend cell pellet in 200 µL of flow cytometry staining buffer.
  6. Centrifuge at 500 × g for 1 min and aspirate supernatant. Wash cells twice with 200 µL of flow cytometry staining buffer.
  7. For surface staining, incubate cells with 50 µL of an antibody cocktail containing anti-CD69, anti-CD25, anti-CD8, anti-PD-1, anti-ICOS, and fixable viability dye for 30 min on ice in the dark.
  8. Wash cells three times with flow cytometry staining buffer to remove unbound antibodies.
  9. Resuspend the cell pellet in 200 µL of 1% paraformaldehyde, and fix cells at RT in dark for 15 min.
    CAUTION: Perform all steps involving paraformaldehyde in a fume hood to prevent inhalation of vapors. Collect all liquid waste containing fixative in a separate container marked for hazardous chemical disposal.
  10. Centrifuge at 500 × g for 1 min and wash once with flow cytometry staining buffer.
  11. Pre-warm 5 × lyse/fix buffer at RT and prepare 1 × working solution with distilled water.
  12. Add 200 µL working solution (1 × lyse/fix buffer) into each well, incubate cells at RT in dark for 30 min.
  13. Wash twice with 1 × permeabilization/wash buffer for phospho-epitope staining. Resuspend the pellet with 1 × permeabilization/wash buffer for phospho-epitope staining and incubate at RT in dark for 10 min.
  14. Centrifuge at 500 × g for 1 min and discard supernatants.
  15. For intracellular staining, incubate cells with 50 µL of an antibody cocktail containing anti-p-S6 for 60 min at RT in the dark.
  16. Wash cells three times with 1 × permeabilization/wash buffer for phospho-epitope staining.
  17. For secondary antibody staining, incubate cells with 50 µL of an antibody cocktail containing anti-rabbit secondary antibody for 30 min on ice in the dark.
  18. Wash cells three times with 1 × permeabilization/wash buffer for phospho-epitope staining and wash once with flow cytometry staining buffer.
  19. Resuspend the cell pellet in 200 µL of flow cytometry staining buffer and acquire samples on the same flow cytometer.
  20. Apply the same gating strategy as described in Section 4.5 and collect at least 1 × 104 CD8+ T cells per sample.
  21. Analyze the median fluorescence intensity (MFI) for each marker using flow cytometry analysis software.

6. Intracellular cytokine blocking and detection

  1. 5 h before harvest, add 100 µL per well of fresh R10 supplemented with PMA (50 ng/mL), ionomycin (1 µg/mL), protein transport inhibitors (monensin) (1:1000) and protein transport inhibitors (brefeldin A–based)(1:1000). Gently mix and return the plates to the 37 °C incubator to block cytokine secretion and allow intracellular accumulation.
  2. At the desired time point, collect cells into a 96-well round-bottom plate.
  3. Centrifuge at 500 × g for 1 min and resuspend cell pellet in 200 µL of flow cytometry staining buffer.
  4. Centrifuge at 500 × g for 1 min and aspirate supernatant. Wash twice with 200 µL of flow cytometry staining buffer.
  5. For surface marker staining, incubate cells with 50 µL of an antibody cocktail containing anti-CD44, anti-CD8 and fixable viability dye for 30 min on ice in the dark.
  6. Wash three times with flow cytometry staining buffer to remove unbound antibodies.
  7. Permeabilize the cells by adding 200 µL of fixation and permeabilization solution and incubate for 30 min on ice in the dark.
    CAUTION: Perform all steps involving Fixation/Permeabilization Solution (containing paraformaldehyde) in a fume hood to prevent inhalation of vapors. Collect all liquid waste containing fixative in a separate container marked for hazardous chemical disposal.
  8. Centrifuge at 500 × g for 1 min and discard the supernatant into hazardous chemical waste.
  9. Wash cells three times with 1 × permeabilization/wash buffer.
  10. For intracellular cytokine staining, incubate with 50 µL of an antibody cocktail containing anti-TNF-α and anti-Granzyme B for 30 min on ice in the dark.
  11. Wash cells three times with 1 × permeabilization/wash buffer to remove unbound antibodies and perform one final wash with flow cytometry staining buffer.
  12. Resuspend the cell pellet in 200 µL of flow cytometry staining buffer and acquire samples on the same flow cytometer.
  13. Apply the same gating strategy as described in Section 4.5 and collect at least 1 × 104 CD8+ T cells per sample. Analyze the percent positivity and MFI for each marker using flow cytometry analysis software.

Access restricted. Please log in or start a trial to view this content.

Results

To investigate the effects of different anti-CD3 stimulation intensities on T cell activation, we isolated murine splenocytes and purified CD8+ T cells for in vitro culture and then performed the T cell activation assays and flow cytometric analysis. For data analysis, lymphocytes were first gated using a combination of FSC-A and SSC-A, followed by gating of singlets via FSC-H and FSC-W, and then SSC-H with SSC-W. Live CD8+ T cells were further gated using CD8 combined with fixable viability dye for...

Access restricted. Please log in or start a trial to view this content.

Discussion

This protocol provides a systematic and reproducible method for studying TCR signal strength-dependent T cell responses. The graded anti-CD3 coating strategy allows precise control over stimulation intensity, enabling researchers to dissect the quantitative relationship between TCR input and downstream functional outcomes. Key procedural points include purification of naive CD8⁺ T cells, precise gradient control of anti-CD3 coating concentration, and strict normalization of cell number per well. To ensure data comp...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (No. T2394504, LY) and the Chief Scientist Research Startup Fund of Lilin Ye (No. R2045, LY).

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
15 mL conical tubeLabgicCD-002-15ASterile 15 mL conical centrifuge tube
4% paraformaldehydeBeyotimeP00994% aqueous fixative for preserving cells before staining
60 mm dishLabgic1221160 mm cell-culture dish
70 µm cell strainerLabgicBS-70-CS70 µm nylon-mesh strainer for preparing single-cell suspensions
96-well round-bottom plateBeyotimeFPT01696-well round-bottom plate for cell culture and staining
ACK lysis bufferBeyotimeC3702Ammonium-chloride-based red blood cell lysis buffer
anti-mouse CD25Biolegend101910APC-conjugated anti-mouse CD25 antibody, clone 3C7, for flow cytometry
anti-mouse CD28Bio X CellBE0015-1Purified anti-mouse CD28 antibody, clone 37.51, for T-cell costimulation
anti-mouse CD3Bio X CellBP0001-1Purified anti-mouse CD3ε antibody, clone 145-2C11, for T-cell activation
anti-mouse CD69BD Biosciences553237PE-conjugated anti-mouse CD69 antibody for activation-marker staining
anti-mouse CD8Invitrogen17-0081-82APC-conjugated anti-mouse CD8a antibody, clone 53-6.7, for flow cytometry
anti-mouse GZMBBiolegend372212PerCP/Cyanine5.5-conjugated anti-human/mouse granzyme B antibody, clone QA16A02, for intracellular flow cytometry
anti-mouse ICOSBD Biosciences565886BV421-conjugated anti-mouse ICOS (CD278) antibody for flow cytometry
anti-mouse PD-1Biolegend135220BV605-conjugated anti-mouse PD-1 (CD279) antibody, clone 29F.1A12, for flow cytometry
anti-mouse TNF-αInvitrogen46-7321-82PerCP-eFluor 710-conjugated anti-mouse TNF-α antibody, clone MP6-XT22, for intracellular flow cytometry
anti-mouse/human CD44Biolegend103030PE/Cyanine7-conjugated anti-mouse/human CD44 antibody, clone IM7, for flow cytometry
biotin anti-mouse CD11bBiolegend101204Biotin-conjugated anti-mouse CD11b antibody for lineage depletion
biotin anti-mouse CD11cBiolegend117304Biotin-conjugated anti-mouse CD11c antibody for lineage depletion
biotin anti-mouse CD16/32Biolegend156604Biotin-conjugated anti-mouse CD16/32 antibody for lineage depletion
biotin anti-mouse CD19Biolegend115504Biotin-conjugated anti-mouse CD19 antibody for lineage depletion
biotin anti-mouse CD4Biolegend100508Biotin-conjugated anti-mouse CD4 antibody for lineage depletion
biotin anti-mouse CD44Biolegend103004Biotin-conjugated anti-mouse CD44 antibody for lineage depletion
biotin anti-mouse CD45RBiolegend103204Biotin-conjugated anti-mouse CD45R/B220 antibody for lineage depletion
biotin anti-mouse CD49bInvitrogen13-5971-85Biotin-conjugated anti-mouse CD49b antibody for lineage depletion
biotin anti-mouse F4/80Biolegend123106Biotin-conjugated anti-mouse F4/80 antibody for lineage depletion
biotin anti-mouse Ly6GBiolegend127604Biotin-conjugated anti-mouse Ly6G antibody for lineage depletion
biotin anti-mouse NK1.1Biolegend108704Biotin-conjugated anti-mouse NK1.1 antibody for lineage depletion
biotin anti-mouse TER119Biolegend116204Biotin-conjugated anti-mouse TER-119 antibody for lineage depletion
C57BL/6 miceSibeifu (Beijing) Biotechnology Co., Ltd.N/A6–8-week-old male mice used for the experiments
Carbon dioxide (CO2) incubatorThermo Fisher3120Humidified CO2 incubator for mammalian cell culture
CellTrace Violet dyeInvitrogenC34557Violet fluorescent dye for monitoring cell proliferation
DMSOSigmaD2650Dimethyl sulfoxide; solvent for preparing reagent stock solutions
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488InvitrogenA-21206Alexa Fluor 488-conjugated donkey anti-rabbit IgG (H+L) secondary antibody
D-PBSVivaCell BiosciencesC3590-0500Dulbecco’s phosphate-buffered saline for washing and reagent preparation
Fetal bovine serum (FBS)GibcoC11995500BTSerum supplement for mammalian cell-culture medium
Fixable Viability DyeInvitrogen65-0865-14Fixable viability dye for excluding dead cells during flow cytometry
Fixation and Permeabilization SolutionBD Biosciences51-2090KZFixation and permeabilization reagent for intracellular staining
Flat-bottom 96-well plateLabgic1151096-well flat-bottom plate for cell culture and stimulation assays
Flow cytometerBD BiosciencesLSRFortessa-3 laserThree-laser flow cytometer for multicolor fluorescence acquisition
Golgi PlugBD Biosciences51-2301KZBrefeldin A-based protein-transport inhibitor for intracellular cytokine staining
Golgi StopBD Biosciences51-2092KZMonensin-based protein-transport inhibitor for intracellular cytokine staining
Ionomycin calcium saltSigmaI3909-1MLCalcium ionophore used with PMA for cell stimulation
Perm/Wash BufferBD Biosciences51-20911KZPermeabilization and wash buffer for intracellular staining
Phosflow Lyse/Fix BufferBD Biosciences5580495× buffer for simultaneous red blood cell lysis and leukocyte fixation
Phosflow Perm/Wash Buffer IBD Biosciences557885Methanol-based permeabilization buffer for intracellular phosphoprotein staining
Phospho-S6 Ribosomal Protein (Ser235/236) (D57.2.2E) Rabbit Monoclonal AntibodyCell Signaling4858SRabbit monoclonal antibody to phospho-S6 ribosomal protein (Ser235/236), clone D57.2.2E
PMASigmaP1585-1MGPhorbol 12-myristate 13-acetate; activator used for ex vivo cell stimulation
Recombinant Mouse Interleukin-2Gibco200-02-50UGRecombinant mouse interleukin-2 for T-cell culture and expansion
RPMI 1640Life-LabAC01L064Roswell Park Memorial Institute 1640 medium for mammalian cell culture
Streptavidin Magnetic BeadsBEAVER22307Streptavidin-coated magnetic beads for biotin-antibody-based cell depletion
Flow cytometry staining bufferNot specifiedNot specifiedFlow cytometry staining buffer; supplier or preparation formula was not provided
Parafilm M laboratory filmAmcorPM996Flexible self-sealing laboratory film for sealing plates, tubes, and culture vessels
Lyse/Fix BufferBD Biosciences5580495× buffer for simultaneous red blood cell lysis and leukocyte fixation
FlowJoBD Biosciencesv10.8.1Software, version 10.8.1, for flow cytometry data analysis

References

  1. De Boer RJ, Yates AJ. Modeling T cell fate. Annu Rev Immunol. 2023;41:513–32.
  2. Chapman NM, Boothby MR, Chi H. Metabolic coordination of T cell quiescence and activation. Nat Rev Immunol. 2020;20(1):55–70.
  3. Liu D, et al. Key links in the physiological regulation of the immune system and disease induction: T cell receptor-CD3 complex. Biochem Pharmacol. 2024;227:116441.
  4. Mariuzza RA, Agnihotri P, Orban J. The structural basis of T-cell receptor (TCR) activation: an enduring enigma. J Biol Chem. 2020;295(4):914–25.
  5. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591–619.
  6. Brownlie RJ, Zamoyska R. T cell receptor signalling networks: branched, diversified and bounded. Nat Rev Immunol. 2013;13(4):257–69.
  7. Au-Yeung BB, et al. Quantitative and temporal requirements revealed for Zap70 catalytic activity during T cell development. Nat Immunol. 2014;15(7):687–94.
  8. Daniels MA, et al. Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. Nature. 2006;444(7120):724–9.
  9. Snook JP, Kim C, Williams MA. TCR signal strength controls the differentiation of CD4+ effector and memory T cells. Sci Immunol. 2018;3(25):eaas9103.
  10. Flaherty S, Reynolds JM. Mouse naïve CD4+ T cell isolation and in vitro differentiation into T cell subsets. J Vis Exp. 2015;(98):e52739.
  11. Trickett A, Kwan YL. T cell stimulation and expansion using anti-CD3/CD28 beads. J Immunol Methods. 2003;275(1–2):251–5.
  12. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2(4):251–62.
  13. Gottschalk RA, et al. Distinct NF-κB and MAPK activation thresholds uncouple steady-state microbe sensing from anti-pathogen inflammatory responses. Cell Syst. 2016;2(6):378–90.
  14. Gjergjova F, et al. A fine-tuned comprehensive overview of antibody-driven ex vivo assays for primary murine T cell activation. J Immunol Methods. 2026;548:114055.
  15. Rosenlehner T, et al. Reciprocal regulation of mTORC1 signaling and ribosomal biosynthesis determines cell cycle progression in activated T cells. Sci Signal. 2024;17(859):eadi8753.
  16. Salmond RJ, Emery J, Okkenhaug K, Zamoyska R. MAPK, phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells. J Immunol. 2009;183(11):7388–97.
  17. Motamedi M, Xu L, Elahi S. Correlation of transferrin receptor (CD71) with Ki67 expression on stimulated human and mouse T cells: the kinetics of expression of T cell activation markers. J Immunol Methods. 2016;437:43–52.
  18. Kalia V, et al. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity. 2010;32(1):91–103.
  19. Caruso A, et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry. 1997;27(1):71–6.
  20. Sutermaster BA, Darling EM. Considerations for high-yield, high-throughput cell enrichment: fluorescence versus magnetic sorting. Sci Rep. 2019;9(1):227.
  21. Llufrio EM, Wang L, Naser FJ, Patti GJ. Sorting cells alters their redox state and cellular metabolome. Redox Biol. 2018;16:381–7.
  22. Quah BJ, Parish CR. New and improved methods for measuring lymphocyte proliferation in vitro and in vivo using CFSE-like fluorescent dyes. J Immunol Methods. 2012;379(1–2):1–14.
  23. Lemieszek MB, Findlay SD, Siegers GM. CellTrace Violet flow cytometric assay to assess cell proliferation. Methods Mol Biol. 2022;2508:101–14.
  24. Whitmire JK, Ahmed R. Costimulation in antiviral immunity: differential requirements for CD4+ and CD8+ T cell responses. Curr Opin Immunol. 2000;12(4):448–55.
  25. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8(4):247–58.
  26. Carbone F, et al. Cellular and molecular signaling towards T cell immunological self-tolerance. J Biol Chem. 2024;300(4):107134.
  27. Daniels MA, Teixeiro E. TCR signaling in T cell memory. Front Immunol. 2015;6:617.
  28. Knudson KM, et al. Cutting edge: the signals for the generation of T cell memory are qualitatively different depending on TCR ligand strength. J Immunol. 2013;191(12):5797–801.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

CD8+ T CellsIn Vitro StimulationAnti-CD3 StimulationAnti-CD28 CostimulationFlow CytometryNaive T Cell IsolationmTORC1 ActivityT Cell Differentiation

This article has been published

Video Coming Soon